NEW YORK, Jan. 26, 2011 /PRNewswire-Asia/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving healthcare through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced that its Chairman and Chief Executive Officer, Mr. Tony Liu and Chief Financial Officer, Ms. Lily Li were Chinese entrepreneur representatives on China's President Hu Jintao's delegation during the official state visit to the United States in January 2011. During the state visit, the management attended various forums and symposiums held by both the U.S. and Chinese government officials. Additionally, the company has signed a US contract research organization (CRO) for its ongoing FDA program.
Mr. Tony Liu, Chairman and CEO of AOBO, commented, "We are greatly honored to have been selected as Chinese entrepreneur representatives on President Hu's delegation. This invitation affirms AOBO's position as a leading pharmaceutical company in China."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter products.
Forward-Looking Statements
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
